Published: Wed, November 22, 2017
World | By Paul Elliott

Cytokinetics, Incorporated (CYTK) added to 19 new portfolios

Cytokinetics, Incorporated (CYTK) added to 19 new portfolios

Cytokinetics, Incorporated disclosed in a document filed with the US Securities and Exchange Commission (SEC) that GC & Chief Compliance Officer Mcdowell Caryn Gordon has sold 4,260 shares of Cytokinetics, Incorporated (CYTK) in trading session dated November 02, 2017.

On Friday, October 6th, Caryn Gordon Mcdowell sold 13,181 shares of Cytokinetics, stock. The return on assets stands at -29.1%, Return on Equity now is -62.6% and the Return on Investment value is 15%.

Cytokinetics, had a negative net margin of 172.27% and a negative return on equity of 62.64%. sell-side analysts forecast that Cytokinetics, Incorporated will post -2.4 earnings per share for the current year. Outstanding shares refer to a company's stock presently held by all its shareholders, counting share blocks held by institutional shareholders and restricted shares owned by the company's officers and insiders. The shares were sold at an average price of $12.94, for a total transaction of $55,124.40. The current consensus recommendation provided by covering analysts is 1.90.

For the current quarter, 7 analysts are projecting a mean EPS of $-0.71/share. A rating of 4 or 5 would represent a Sell recommendation. Cytokinetics, has a 52-week low of $7.00 and a 52-week high of $17.20. After a recent check, it is observed that the insiders for the firm now own 0.40% shares. Active and passive investors always require every bit of information available regarding his chosen security and this include keeping close watch on fundamental and technical data. Also, Director Santo J. Costa sold 5,000 shares of the company's stock in a transaction that occurred on Tuesday, August 29th. BNP Paribas Arbitrage SA now owns 13,328 shares of the biopharmaceutical company's stock valued at $161,000 after purchasing an additional 13,036 shares during the last quarter. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the company. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.04. ValuEngine raised shares of Cytokinetics, from a "sell" rating to a "hold" rating in a research report on Friday, September 1st. In a report issued on October 29, Cowen analyst Ritu Baral reiterated a Buy rating on CYTK, with a price target of $19, which represents a potential upside of 71% from where the stock is now trading.

US stocks are opening higher Tuesday as most industries, including technology and health care companies, start the day with solid gains. Municipal Employees Retirement System of MI purchased a new position in Cytokinetics, in the second quarter worth $132,000. Ameriprise Financial Inc. purchased a new position in shares of Cytokinetics, during the second quarter valued at approximately $2,914,000. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States & global copyright & trademark laws. Piedmont Investment Advisors LLC purchased a new stake in Cytokinetics, in the third quarter valued at approximately $159,000. Finally, BNP Paribas Arbitrage SA grew its stake in shares of Cytokinetics, by 4,464.4% in the 2nd quarter. This gauge is crucial in determining whether investors are moved toward the direction of buying more of the stock, or else doing the contradictory side and selling more of the stock.

Cytokinetics (NASDAQ:CYTK) has trailing twelve month Return on Assets of -29.1%, which is key indicator of how profitable a company is relative to its total assets.

Cytokinetics trial failure is another setback for ALS drug development, which has produced few treatments for the neurodegenerative condition best known as Lou Gehrig's disease. "That is where our strategy as a company goes from ALS and other diseases of severe neuromuscular dysfunction in the near term to a goal to develop both skeletal and cardiac muscle activators for an aging population", Blum said.

Like this: